Exelixis, Inc. (EXEL)

Exelixis Inc. (NASDAQ:EXEL) is one of the best low priced growth stocks to invest in now. On May 5, Exelixis reported total revenues of $610.8 million for Q1 2026, up from $555.4 million in Q1 2025. This increase was driven primarily by US net product revenues of $555 million from its cabozantinib .…

The answer is “denominator effect”: while EXEL’s underlying net income has grown 92.2% annually in the last three years, its earnings per share (EPS) have expanded at 106.5%. What does this contribute to? Steady capital gain. In the last 3 years, the stock returned 152% in price appreciation ...

Results for the first half of 2025–2026Earnings were negatively impacted by lower volumes due to unfavorable market cycles. In this context, the Group has...

Once again, as a reminder, our earnings press release and Form 10-Q present a full reconciliation of our non-GAAP measures of the most directly comparable GAAP measures. Now turning to our balance sheet and liquidity. As of March 31, 2026, the company's balance sheet reflected stockholders' equity .…

A number of research firms have changed their ratings and price targets for Exelixis (NASDAQ: EXEL): 5/19/2026 – Exelixis had its “buy (b)” rating reaffirmed by Weiss Ratings. 5/9/2026 – Exelixis was upgraded by Wall Street Zen from “buy” to “strong-buy”. 5/7/2026 – Exelixis ...